ZHEJIANG TAILIN BIOENGINEERING CO.,LTD Zhejiang Tailin BioEngineering Co.,Ltd Stock
Equities
300813
CNE100003S89
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.13 CNY | +1.45% |
|
+8.99% | -34.22% |
| Sales 2022 | 374M 51.64M 70.49M | Sales 2023 | 270M 37.27M 50.88M | Capitalization | 2.66B 368M 502M |
|---|---|---|---|---|---|
| Net income 2022 | 79M 10.91M 14.89M | Net income 2023 | 19M 2.62M 3.58M | EV / Sales 2022 | 9.18 x |
| Net cash position 2022 | 432M 59.63M 81.39M | Net cash position 2023 | 239M 33.07M 45.13M | EV / Sales 2023 | 8.99 x |
| P/E ratio 2022 |
50.5
x | P/E ratio 2023 |
144
x | Employees | 836 |
| Yield 2022 |
0.65% | Yield 2023 |
-
| Free-Float | 31.38% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.45% | ||
| 1 week | +8.99% | ||
| Current month | -16.38% | ||
| 1 month | -12.10% | ||
| 3 months | -23.59% | ||
| 6 months | -34.70% | ||
| Current year | -34.22% |
1 week
14.81
16.15
1 month
13.7020.84
Current year
11.0124.84
1 year
11.0131.17
3 years
11.0166.83
5 years
11.0166.83
10 years
11.0166.83
| Managers | Title | Age | Since |
|---|---|---|---|
Da Lin Ye
CEO | Chief Executive Officer | 63 | 02-01-07 |
Xing Yue Ye
DFI | Director of Finance/CFO | 50 | 15-04-27 |
Mei Zhu Hu
CTO | Chief Tech/Sci/R&D Officer | 55 | 15-04-27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Zhong Zhi Yang
BRD | Director/Board Member | 63 | 19-06-19 |
Da Lin Ye
CEO | Chief Executive Officer | 63 | 02-01-07 |
Wei Ju Ni
BRD | Director/Board Member | 65 | 15-04-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 16.13 | +1.45% | 1,657,413 |
| 24-04-25 | 15.9 | +1.86% | 1,307,476 |
| 24-04-24 | 15.61 | +2.16% | 1,426,310 |
| 24-04-23 | 15.28 | +3.38% | 1,547,508 |
| 24-04-22 | 14.78 | -0.14% | 1,008,453 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Zhejiang Tailin Bioengineering Co., Ltd. is a China-based company mainly engaged in pharmaceutical equipment business. The Company's main business is the research, development, manufacturing and sales of microbial detection and control technology system products, organic substance analysis instruments and other pharmaceutical equipment. Specific products include various consumables, instruments and equipment, which can be used alone or in combination for the production and quality of sterile drugs. The application areas that can be expanded include medical and health, food safety, disease prevention and control, biosecurity, inspection and quarantine, biological engineering, laboratory animals, and environmental protection. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-14
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -34.22% | 242M | |
| +8.94% | 219B | |
| +7.48% | 183B | |
| +11.34% | 133B | |
| +25.35% | 108B | |
| +0.61% | 63.06B | |
| +12.49% | 52.02B | |
| -0.62% | 48.2B | |
| +0.08% | 40.37B | |
| +13.24% | 39.35B |
- Stock Market
- Equities
- 300813 Stock
